MarketPeel
Insider Trading Intelligence
SR

Scott T. Rottinghaus

ENTA
CHIEF MEDICAL OFFICER · ENANTA PHARMACEUTICALS INC · CIK 0001942407
FILING MIX · LIFETIME48%/52%
BUYS
12
SELLS
13
TOTAL VALUE
$396.0K
COMPANIES
1
ACTIVE SINCE
Aug 2022
HOLDINGS NOW
25,254
AVG SELL PX
$13.21
TRADE KIND
SHOWING 25 / 25
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 6 pending
Forward-return performance of every backtestable P/S trade by Scott T. Rottinghaus, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+83.33%-8.74%-0.57%-8.17%-7.62%
14d6+66.67%-4.44%-1.29%-3.15%-2.15%
30d6+83.33%-12.83%-1.80%-11.02%-14.98%
60d6+83.33%-14.15%+0.81%-14.96%-21.43%
90d6+83.33%-7.44%+3.03%-10.46%-18.92%
180d6+83.33%-33.17%+6.31%-42.59%-70.50%
1y6(1 pending)+80.00%-20.56%+17.16%-37.73%-69.36%
2y6(5 pending)+0.00%+48.79%+52.88%-4.10%-4.10%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ENTA · 25,254 shares · as of Feb 12, 2026
027,50055,00082,500110,0002023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 12 buys / 13 sellsCOVERAGE · 15 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
1,65023,442Feb 12, 2026Feb 13, 2026View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
5,22528,667Feb 12, 2026Feb 13, 2026View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Medical Officer
3,413$14.25$48.6K25,254Feb 12, 2026Feb 13, 2026View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Medical Officer
798$14.23$11.4K21,792Dec 5, 2025Dec 5, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
110,000110,000Nov 25, 2025Nov 26, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Medical Officer
2,217$6.99$15.5K22,590Aug 8, 2025Aug 8, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
9,75027,668Feb 12, 2025Feb 14, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Medical Officer
2,861$5.59$16.0K24,807Feb 12, 2025Feb 14, 2025View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
866$8.06$7.0K17,918Dec 6, 2024Dec 10, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
87,00087,000Nov 27, 2024Nov 27, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Medical Officer
1,466$12.73$18.7K18,784Aug 8, 2024Aug 9, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Medical Officer
5,37580,625Jul 15, 2024Jul 15, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
5,375$17.08$91.8K21,717Jul 15, 2024Jul 15, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASE
Chief Medical Officer
5,375$8.99$48.3K27,092Jul 15, 2024Jul 15, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
2,271$15.04$34.2K21,717Jul 12, 2024Jul 15, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE10b5-1
10b5-1 plan
4,299$15.07$64.8K23,988Jul 11, 2024Jul 15, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Medical Officer
755$12.41$9.4K28,287Feb 12, 2024Feb 14, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
2,57629,042Feb 12, 2024Feb 14, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Sr. VP & CMO
534$9.63$5.1K26,466Dec 5, 2023Dec 6, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
86,00086,000Nov 22, 2023Nov 22, 2023View →
ENTA
ENANTA PHARMACEUTICALS INC
SALE
Chief Medical Officer
1,467$17.23$25.3K25,533Aug 8, 2023Aug 9, 2024View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
7,00027,000Nov 23, 2022Nov 28, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
15,00015,000Nov 23, 2022Nov 28, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
20,00020,000Aug 8, 2022Aug 10, 2022View →
ENTA
ENANTA PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
75,00075,000Aug 8, 2022Aug 10, 2022View →
Other insiders · ENTA
Loading peer insiders…
About this filer
CIK 0001942407
ROLE
Chief Medical Officer
PRIMARY
ENTA
COMPANIES
1
ACTIVE SINCE
Aug 2022
MARKETPEEL · /INSIDER/0001942407DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback